Evidence map›Paper›PMID 24521050›Full record

ReviewExpert opinion on drug delivery2014

Cutaneous immunization: an evolving paradigm in influenza vaccines.

Harvinder S Gill, Sang-Moo Kang, Fu-Shi Quan, Richard W Compans

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on drug delivery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Polymeric microneedles for transdermal protein delivery.Advanced drug delivery reviews · 2018
    Review
  9. Article
  10. Article
  11. Article
  12. Mucosal vaccine delivery: Current state and a pediatric perspective.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Harvinder S GillTexas Tech University, Department of Chemical Engineering , Lubbock, TX , USA.
Sang-Moo Kang
Fu-Shi Quan
Richard W Compans
Emory University · USGeorgia State University · USKyung Hee University · KRTexas Tech University · US

Funding

Influenza vaccination using a microneedle patchU01EB012495 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2010 to 2015
$9.6M
Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
VLP Vaccine TechnologyR01AI105170 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2013 to 2017
$3.7M
NIAID NIH HHS AI093772NIAID NIH HHS AI105170NIAID NIH HHS R01 AI093772NIAID NIH HHS R01 AI105170NIBIB NIH HHS EB012495NIBIB NIH HHS U01 EB012495
6 · The paper itself

Abstract

introductionMost vaccines are administered by intramuscular injection using a hypodermic needle and syringe. Some limitations of this procedure include reluctance to be immunized because of fear of needlesticks, and concerns associated with the safe disposal of needles after their use. Skin delivery is an alternate route of vaccination that has potential to be painless and could even lead to dose reduction of vaccines. Recently, microneedles have emerged as a novel painless approach for delivery of influenza vaccines via the skin. AREAS COVERED: In this review, we briefly summarize the approaches and devices used for skin vaccination, and then focus on studies of skin immunization with influenza vaccines using microneedles. We discuss both the functional immune response and the nature of this immune response following vaccination with microneedles. EXPERT OPINION: The cutaneous administration of influenza vaccines using microneedles offers several advantages: it is painless, elicits stronger immune responses in preclinical studies and could improve responses in high-risk populations. These dry formulations of vaccines provide enhanced stability, a property of high importance in enabling their rapid global distribution in response to possible outbreaks of pandemic influenza and newly emerging infectious diseases.

Indexed as

Drug Delivery SystemsAdministration, CutaneousChemistry, PharmaceuticalHumansImmunizationInfluenza VaccinesInjections, IntradermalSkinInfluenza Vaccines

Identifiers

PMID24521050
PMCPMC4009492
OpenAlexW2082562453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.